ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses
May 03 2007 - 4:00AM
PR Newswire (US)
ADVENTRX Presents Results at International Conference on Antiviral
Research SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that it presented results demonstrating synergistic
activity against human and avian influenza (bird flu) viruses when
the Company's broad-spectrum antiviral drug candidate, ANX-201
(thiophosphonoformic acid), was combined with oseltamivir phosphate
(Tamiflu(R)) in preclinical tests. ANX-201 also demonstrated single
agent antiviral activity against these viruses. The results were
presented at the International Conference on Antiviral Research
(ICAR) in Palm Springs, CA on Wednesday, May 2nd. "These results
suggest we can simultaneously improve efficacy and lower dosages
with a two drug regimen of ANX-201 and Tamiflu," said Evan M.
Levine, chief executive officer of ADVENTRX. "We intend to continue
to investigate the use of ANX-201 in avian flu." As a single agent,
ANX-201 showed dose-dependent antiviral activity against human,
equine and avian influenza virus. Fixed-dose combinations of
ANX-201 and the neuraminidase inhibitor Tamiflu produced a
supra-additive, or synergistic, antiviral activity against the
human and avian influenza viruses, as demonstrated by an overall
lowering of the drug concentrations required to achieve virus
inhibition. ANX-201 dosage could be reduced up to 10 fold against
human influenza strains H3N2 and H1N1, and up to 100 fold against
avian influenza strain H5N2 when administered in combination with
Tamiflu. Tests were performed in vitro using standard cell-based
influenza infectivity assays. A copy of the poster presentation is
available for download from the "Resources" section of the
Company's web site at http://www.adventrx.com/ under
"Publications." About ANX-201 ANX-201 (thiophosphonoformic acid) is
a pyrophosphate analog and member of a new class of reverse
transcriptase inhibitor (RTI) for HIV. ANX-201 has shown activity
against HIV drug-resistant clinical isolates and has shown synergy
with nucleoside RTIs (NRTIs) in preclinical studies. The resistance
profile of ANX-201 is unique among approved RTIs and contains
mutations that have been shown to resensitize NRTI-resistant virus.
In preclinical studies, ANX-201 has shown broad-spectrum antiviral
activity against HIV-1, HIV-2, human and avian influenza viruses,
and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2). ADVENTRX
plans to initiate a Phase 1/2 clinical trial of ANX-201 as a
component of multi-drug therapy for the treatment of HIV during
2007. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can
be found on the Company's web site at http://www.adventrx.com/.
Forward Looking Statement ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks
and assumptions that, if they materialize or do not prove to be
accurate, could cause ADVENTRX's results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: the validity of research results; the risk
that preclinical results are not indicative of the success of
subsequent clinical trials and that products will not perform as
preclinical data suggests or as otherwise anticipated; unexpected
adverse side effects or inadequate therapeutic efficacy of ANX-201
and other uncertainties inherent in the drug development process;
the timing and success of clinical trials; difficulties or delays
in developing, testing, manufacturing, and obtaining regulatory
approval for ANX-201, including receiving necessary regulatory
approvals for a Phase 1/2 clinical trial of ANX-201; the risk that
ADVENTRX will be unable to raise sufficient capital to fund the
projects necessary to meet its anticipated or stated goals and
milestones, including funding the continued development of ANX-201
for the treatment of HIV or human or avian influenza; and other
risks and uncertainties more fully described in ADVENTRX's press
releases and public filings with the Securities and Exchange
Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov/. ADVENTRX
does not intend to update any forward-looking statement, including
as set forth in this press release, to reflect events or
circumstances arising after the date on which it was made.
DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors,
Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866; or
Media, Amy Martini of WeissComm Partners, +1-212-301-7223, for
ADVENTRX Pharmaceuticals Web site: http://www.adventrx.com/ Company
News On-Call: http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024